Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations i… Read more
Marinus Pharmaceuticals Inc (MRNS) - Total Assets
Latest total assets as of September 2024: $63.62 Million USD
Based on the latest financial reports, Marinus Pharmaceuticals Inc (MRNS) holds total assets worth $63.62 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Marinus Pharmaceuticals Inc - Total Assets Trend (2012–2023)
This chart illustrates how Marinus Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Marinus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Marinus Pharmaceuticals Inc's total assets of $63.62 Million consist of 96.7% current assets and 3.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.6% |
| Accounts Receivable | $3.80 Million | 2.2% |
| Inventory | $2.41 Million | 1.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Marinus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Marinus Pharmaceuticals Inc's current assets represent 96.7% of total assets in 2023, a decrease from 99.8% in 2012.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2023, down from 99.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Marinus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Marinus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Marinus Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Marinus Pharmaceuticals Inc generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Marinus Pharmaceuticals Inc is currently not profitable relative to its asset base.
Marinus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 6.38 | 11.72 |
| Quick Ratio | 1.47 | 6.29 | 11.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.90 Million | $ 164.49 Million | $ 86.10 Million |
Marinus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Marinus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -34.1% |
| Total Assets | $170.91 Million |
| Market Capitalization | $20.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Marinus Pharmaceuticals Inc's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Marinus Pharmaceuticals Inc's assets decreased by 34.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Marinus Pharmaceuticals Inc (2012–2023)
The table below shows the annual total assets of Marinus Pharmaceuticals Inc from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $170.91 Million | -34.14% |
| 2022-12-31 | $259.52 Million | +89.65% |
| 2021-12-31 | $136.84 Million | -9.05% |
| 2020-12-31 | $150.46 Million | +52.22% |
| 2019-12-31 | $98.84 Million | +31.38% |
| 2018-12-31 | $75.23 Million | +24.00% |
| 2017-12-31 | $60.67 Million | +92.93% |
| 2016-12-31 | $31.45 Million | -47.29% |
| 2015-12-31 | $59.66 Million | +18.82% |
| 2014-12-31 | $50.21 Million | +324.67% |
| 2013-12-31 | $11.82 Million | +36.19% |
| 2012-12-31 | $8.68 Million | -- |